Possible role of milk-derived bioactive peptides in the treatment and prevention of metabolic syndrome

Nutrition Reviews

Volumn 70, Issue 4, 2012, Pages 241-255

  Ricci Cabello, Ignacio ^a,b   Olalla Herrera, Manuel ^c   Artacho, Reyes ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Bioactive peptides; Metabolic syndrome; Milk proteins

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; BETA CASEIN; BETA CASEIN F; BETA LACTOGLOBULIN; BIOACTIVE PEPTIDE; CASOPLATELIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN; LACTOFERRIN; LACTOSTATIN; LACTOTRIPEPTIDE; ME 3; MILK PROTEIN; NITRIC OXIDE PEPTIDE 47; PEPTIDE DERIVATIVE; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FATTY ACID OXIDATION; HUMAN; HYPERTENSION; LACTOBACILLUS FERMENTUM; LACTOBACILLUS HELVETICUS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; SACCHAROMYCES CEREVISIAE; SATIETY; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; VASODILATATION; WEIGHT REDUCTION;

FUNCTIONAL FOOD; HUMANS; METABOLIC SYNDROME X; MILK PROTEINS; PEPTIDES;

EID: 84859128676     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2011.00448.x     Document Type: Review

References (162)

1. Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr. 2010;140:648-652.
2. Ott C, Schmieder RE. The role of statins in the treatment of the metabolic syndrome. Curr Hypertens Rep. 2009;11:143-149.
3. WHO. Cardiovascular Diseases 2011. Available at: Accessed 26 September 2011.
4. Strong K, Mathers C, Epping-Jordan J, etal. Preventing chronic disease: a priority for global health. Int J Epidemiol. 2006;35:492-494.
5. Tremblay A, Gilbert JA. Milk products, insulin resistance syndrome and type 2 diabetes. J Am Coll Nutr. 2009;28(Suppl 1):S91-S102.
6. Elwood PC, Pickering JE, Givens DI, etal. The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. Lipids. 2010;45:925-939.
7. Pfeuffer M, Schrezenmeir J. Milk and the metabolic syndrome. Obes Rev. 2007;8:109-118.
8. van Meijl LE, Vrolix R, Mensink RP. Dairy product consumption and the metabolic syndrome. Nutr Res. 2008;21:148-157.
9. Korhonen H, Pihlanto A. Technological options for the production of health-promoting proteins and peptides derived from milk and colostrum. Curr Pharm Des. 2007;13:829-843.
10. Hayes M, Stanton C, Fitzgerald GF, etal. Putting microbes to work: dairy fermentation, cell factories and bioactive peptides. Part II: bioactive peptide functions. Biotechnol J. 2007;2:435-449.
11. Meisel H. Biochemical properties of peptides encrypted in bovine milk proteins. Curr Med Chem. 2005;12:1905-1919.
12. Fitzgerald GF, Murray BA. Bioactive peptides and lactic fermentations. Int J Dairy Technol. 2006;59:118-125.
13. Hayes M, Ross RP, Fitzgerald GF, etal. Putting microbes to work: dairy fermentation, cell factories and bioactive peptides. Part I: overview. Biotechnol J. 2007;2:426-434.
14. Hernández-Ledesma B, Dávalos A, Bartolomé B, etal. Preparation of antioxidant enzymatic hydrolysates from α-lactalbumin and β-lactoglobulin. Identification of active peptides by HPLC-MS/MS. J Agric Food Chem. 2005;53:588-593.
15. Pan Y, Lee A, Wan J, etal. Antiviral properties of milk proteins and peptides. Int Dairy J. 2006;16:1252-1261.
16. Hartmann R, Meisel H. Food-derived peptides with biological activity: from research to food applications. Curr Opin Biotechnol. 2007;18:163-169.
17. Hernández-Ledesma B, Contreras M, Recio I. Antihypertensive peptides: production, bioavailability and incorporation into foods. Adv Colloid Interface Sci. 2011;165:23-35.
18. Erdmann K, Cheung BW, Schroder H. The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. J Nutr Biochem. 2008;19:643-654.
19. Manso MA, López-Fandiño R. κ-Casein macropeptides from cheese whey: physicochemical, biological, nutritional, and technological features for possible uses. Food Rev Int. 2004;20:329-355.
20. Pihlanto-Leppala A, Korhonen H. Bioactive peptides and proteins. Adv Food Nutr Res. 2003;47:175-276.
21. Meisel H, Frister H, Schlimme E. Biologically active peptides in milk proteins. Z Ernahrungswiss. 1989;28:267-278.
22. Aimutis WR. Bioactive properties of milk proteins with particular focus on anticariogenesis. J Nutr. 2004;134:S989-S995.
23. Bitri L. Optimization study for the production of an opioid-like preparation from bovine casein by mild acidic hydrolysis. Int Dairy J. 2004;14:535-539.
24. Heddleson RA, Park O, Allen JC. Immunogenicity of casein phosphopeptides derived from tryptic hydrolysis of beta-casein. J Dairy Sci. 1997;80:1971-1976.
25. Korhonen H, Pihlanto A. Food-derived bioactive peptides - opportunities for designing future foods. Curr Pharm Des. 2003;9:1297-1308.
26. LeBlanc JG, Matar C, Valdez JC, etal. Immunomodulating effects of peptidic fractions issued from milk fermented with Lactobacillus helveticus. J Dairy Sci. 2002;85:2733-2742.
27. Li EW, Mine Y. Immunoenhancing effects of bovine glycomacropeptide and its derivatives on the proliferative response and phagocytic activities of human macrophagelike cells, U937. J Agric Food Chem. 2004;52:2704-2708.
28. Matar C, Valdez JC, Medina M, etal. Immunomodulating effects of milks fermented by Lactobacillus helveticus and its non-proteolytic variant. J Dairy Res. 2001;68:601-609.
29. Meisel H, FitzGerald RJ. Biofunctional peptides from milk proteins: mineral binding and cytomodulatory effects. Curr Pharm Des. 2003;9:1289-1295.
30. Zimecki M, Kruzel ML. Milk-derived proteins and peptides of potential therapeutic and nutritive value. J Exp Ther Oncol. 2007;6:89-106.
31. Ricci I, Artacho R, Olalla M. Milk protein peptides with angiotensin I-converting enzyme inhibitory (ACEI) activity. Crit Rev Food Sci Nutr. 2010;50:390-402.
32. Morikawa K, Kondo I, Kanamaru Y, etal. A novel regulatory pathway for cholesterol degradation via lactostatin. Biochem Biophys Res Commun. 2007;352:697-702.
33. Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr Mol Med. 2001;1:633-653.
34. Severin S, Wenshui X. Milk biologically active components as nutraceuticals: review. Crit Rev Food Sci Nutr. 2005;45:645-656.
35. Solah VA, Kerr DA, Adikara CD, etal. Differences in satiety effects of alginate- and whey protein-based foods. Appetite. 2010;54:485-491.
36. Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake and satiety. J Am Coll Nutr. 2007;26:S704-S712.
37. Madureira AR, Tavares T, Gomes AM, etal. Invited review: physiological properties of bioactive peptides obtained from whey proteins. J Dairy Sci. 2010;93:437-455.
38. Beucher S, Levenez F, Yvon M, etal. Effects of gastric digestive products from casein on CCK release by intestinal cells in rat. J Nutr Biochem. 1994;5:578-584.
39. Yvon M, Beucher S, Guilloteau P, etal. Effects of caseinomacropeptide (CMP) on digestion regulation. Reprod Nutr Dev. 1994;34:527-537.
40. Pedersen NL, Nagain-Domaine C, Mahe S, etal. Caseinomacropeptide specifically stimulates exocrine pancreatic secretion in the anesthetized rat. Peptides. 2000;21:1527-1535.
41. Gustafson DR, McMahon DJ, Morrey J, etal. Appetite is not influenced by a unique milk peptide: caseinomacropeptide (CMP). Appetite. 2001;36:157-163.
42. Lam SM, Moughan PJ, Awati A, etal. The influence of whey protein and glycomacropeptide on satiety in adult humans. Physiol Behav. 2009;96:162-168.
43. Keogh JB, Clifton P. The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr. 2008;87:1602-1605.
44. Keogh JB, Woonton BW, Taylor CM, etal. Effect of glycomacropeptide fractions on cholecystokinin and food intake. Br J Nutr. 2010;104:286-290.
45. Nishi T, Hara H, Hira T, etal. Dietary protein peptic hydrolysates stimulate cholecystokinin release via direct sensing by rat intestinal mucosal cells. Exp Biol Med (Maywood). 2001;226:1031-1036.
46. Froetschel MA, Azain MJ, Edwards GL, etal. Opioid and cholecystokinin antagonists alleviate gastric inhibition of food intake by premeal loads of casein in meal-fed rats. J Nutr. 2001;131:3270-3276.
47. Pupovac J, Anderson GH. Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats. J Nutr. 2002;132:2775-2780.
48. Daniel H, Vohwinkel M, Rehner G. Effect of casein and α-casomorphins on gastrointestinal mobility in rats. J Nutr. 1990;120:252-257.
49. Aziz A, Anderson GH. Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats. J Nutr. 2003;133:2326-2330.
50. Hall WL, Millward DJ, Long SJ, etal. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr. 2003;89:239-248.
51. Bonithon-Kopp C, Coudray C, Berr C, etal. Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59-71y: the EVA Study. Etude sur le Vieillisement Arteriel. Am J Clin Nutr. 1997;65:121-127.
52. Gale CR, Ashurst HE, Powers HJ, etal. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr. 2001;74:402-408.
53. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008;70:193-219.
54. Elias RJ, Kellerby SS, Decker EA. Antioxidant activity of proteins and peptides. Crit Rev Food Sci Nutr. 2008;48:430-441.
55. Hernandez-Ledesma B, Amigo L, Recio I, etal. ACE-inhibitory and radical-scavenging activity of peptides derived from beta-lactoglobulin f(19-25). Interactions with ascorbic acid. J Agric Food Chem. 2007;55:3392-3397.
56. Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003;9:1309-1323.
57. Kullisaar T, Songisepp E, Mikelsaar M, etal. Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects. Br J Nutr. 2003;90:449-456.
58. Muller N, Scholz-Ahrens K, Roos N, etal. Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr. 2008;47:171-182.
59. Saito K, Jin DH, Ogawa T, etal. Antioxidative properties of tripeptide libraries prepared by the combinatorial chemistry. J Agric Food Chem. 2003;51:3668-3674.
60. Alabovsky VV, Boldyrev AA, Vinokurov AA, etal. Effect of histidine-containing dipeptides on isolated heart under ischemia/reperfusion. Biochemistry (Mosc). 1997;62:77-87.
61. Erdmann K, Grosser N, Schipporeit K, etal. The ACE inhibitory dipeptide Met-Tyr diminishes free radical formation in human endothelial cells via induction of heme oxygenase-1 and ferritin. J Nutr. 2006;136:2148-2152.
62. Takenaka A, Annaka H, Kimura Y, etal. Reduction of paraquat-induced oxidative stress in rats by dietary soy peptide. Biosci Biotechnol Biochem. 2003;67:278-283.
63. Peña-Ramos EA, Xiong Y, Arteaga GE. Fractionation and characterisation for antioxidant activity of hydrolysed whey protein. J Sci Food Agric. 2004;84:1908-1918.
64. Chen HM, Muramoto K, Yamauchi F, etal. Antioxidative properties of histidine-containing peptides designed from peptide fragments found in the digests of a soybean protein. J Agric Food Chem. 1998;46:49-53.
65. Pihlanto A. Antioxidative peptides derived from milk proteins. Int Dairy J. 2006;16:1306-1314.
66. Suetsuna K, Ukeda H, Ochi H. Isolation and characterization of free radical scavenging activities peptides derived from casein. J Nutr Biochem. 2000;11:128-131.
67. Rival SG, Fornaroli S, Boeriu CG, etal. Caseins and casein hydrolysates. 1. Lipoxygenase inhibitory properties. J Agric Food Chem. 2001;49:287-294.
68. Rival SG, Boeriu CG, Wichers HJ. Caseins and casein hydrolysates. 2. Antioxidative properties and relevance to lipoxygenase inhibition. J Agric Food Chem. 2001;49:295-302.
69. Kudoh Y, Matsuda S, Igoshi K, etal. Antioxidative peptide from milk fermented with Lactobacillus delbrueckii subsp. bulgaricus IFO13953. Nippon Shokuhin Kagaku Kaishi. 2001;48:44-45.
70. Diaz M, Decker EA. Antioxidant mechanisms of caseinophosphopeptides and casein hydrolysates and their application in ground beef. J Agric Food Chem. 2004;52:8208-8213.
71. Zommara M, Toubo H, Sakono M, etal. Prevention of peroxidative stress in rats fed on a low vitamin E-containing diet by supplementing with a fermented bovine milk whey preparation: effect of lactic acid and beta-lactoglobulin on the antiperoxidative action. Biosci Biotechnol Biochem. 1998;62:710-717.
72. Le Brocq M, Leslie SJ, Milliken P, etal. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal. 2008;10:1631-1674.
73. Hirota T, Ohki K, Kawagishi R, etal. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res. 2007;30:489-496.
74. Jakala P, Hakala A, Turpeinen AM, etal. Casein-derived bioactive tripeptides Ile-Pro-Pro and Val-Pro-Pro attenuate the development of hypertension and improve endothelial function in salt-loaded Goto-Kakizaki rats. J Func Foods. 2009;1:366-374.
75. Jauhiainen T, Ronnback M, Vapaatalo H, etal. Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin.Nutr. 2010;64:424-431.
76. Sipola M, Finckenberg P, Vapaatalo H, etal. α-lactorphin and β-lactorphin improve arterial function in spontaneously hypertensive rats. Life Sci. 2002;71:1245-1253.
77. Jauhiainen T, Ronnback M, Vapaatalo H, etal. Lactobacillus helveticus fermented milk reduces arterial stiffness in hypertensive subjects. Int Dairy J. 2007;17:1209-1211.
78. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
79. Sugano M, Goto S, Yamada Y, etal. Cholesterol-lowering activity of various undigested fractions of soybean protein in rats. J Nutr. 1990;120:977-985.
80. Ronis MJ, Chen Y, Badeaux J, etal. Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J Nutr. 2009;139:1431-1438.
81. Wergedahl H, Liaset B, Gudbrandsen OA, etal. Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats. J Nutr. 2004;134:1320-1327.
82. Nagaoka S, Kanamaru Y, Kojima T, etal. Comparative studies on the serum cholesterol lowering action of whey protein and soybean protein in rats. Biosci Biotechnol Biochem. 1992;56:1484-1485.
83. Zhang X, Beynen AC. Lowering effect of dietary milk-whey protein v. casein on plasma and liver cholesterol concentrations in rats. Br J Nutr. 1993;70:139-146.
84. Nagaoka S, Kanamaru Y, Kuzaya Y. Effect of whey protein and casein on the plasma and liver lipid in rats. Agric Biol Chem. 1991;55:813-818.
85. Nagaoka S, Futamura Y, Miwa K, etal. Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin. Biochem Biophys Res Commun. 2001;281:11-17.
86. Fosset S, Tome D. Dietary protein-derived peptides with antithrombotic activity. Bull Int Dairy Fed. 2000;353:65-68.
87. Caen J, Jolles P, Bal dit Sollier C, etal. Anti-thrombotic activity of milk protein peptide sequences[in French]. Cahiers de Nutrition et de Dietetique. 1992;27:33-35.
88. Jolles P, Levy-Toledano S, Fiat AM, etal. Analogy between fibrinogen and casein. Effect of an undecapeptide isolated from κ-casein on platelet function. Eur J Biochem. 1986;158:379-382.
89. Fiat AM, Jolles P. Caseins of various origins and biologically active casein peptides and oligosaccharides: structural and physiological aspects. Mol Cell Biochem. 1989;87:5-30.
90. Fiat AM, Migliore-Samour D, Jolles P, etal. Biologically active peptides from milk proteins with emphasis on two examples concerning antithrombotic and immunomodulating activities. J Dairy Sci. 1993;76:301-310.
91. Mazoyer EC, Bal dit Sollier C, Drouet L, etal. Active peptides from human and cow's milk proteins: effects on platelets function and vessel wall. In: Paubert-Braquet M, Dupont CH, Paoletti R, eds. Foods, Nutrition, and Immunity. Vol. I. Basel: Karger; 1992:8895.
92. Shebuski RJ, Ramjit DR, Bencen GH, etal. Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. J Biol Chem. 1989;264:21550-21556.
93. Drouet L, Bal dit SC, Cisse M, etal. The antithrombotic effect of KRDS, a lactotransferrin peptide, compared with RGDS. Nouv Rev Fr Hematol. 1990;32:59-62.
94. Rutherfurd KJ, Gill HS. Peptides affecting coagulation. Br J Nutr. 2000;84(Suppl 1):S99-S102.
95. Dionysius DA, Marschke RJ, Wood AJ, etal. Identification of physiologically functional peptides in dairy products. Aust J Dairy Technol. 2000;55:103-103.
96. Hernandez-Ledesma B, Amigo L, Ramos M, etal. Angiotensin converting enzyme inhibitory activity in commercial fermented products. Formation of peptides under simulated gastrointestinal digestion. J Agric Food Chem. 2004;52:1504-1510.
97. Gobbetti M, Minervini F, Rizzello CG. Angiotensin I-converting-enzyme-inhibitory and antimicrobial bioactive peptides. Int J Dairy Technol. 2004;57:173-188.
98. Franklin SS. Systolic blood pressure: it's time to take control. Am J Hypertens. 2004;17:S49-S54.
99. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J Nutr. 2004;134:S980-S988.
100. Geleijnse JM, Engberink MF. Lactopeptides and human blood pressure. Curr Opin Lipidol. 2010;21:58-63.
101. Wuerzner G, Peyrard S, Blanchard A, etal. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens. 2009;27:1404-1409.
102. Kris-Etherton PM, Grieger JA, Hilpert KF, etal. Milk products, dietary patterns and blood pressure management. J Am Coll Nutr. 2009;28(Suppl 1):S103-S119.
103. Meyer J, Butikofer U, Walther B, etal. Hot topic: changes in angiotensin-converting enzyme inhibition and concentrations of the tripeptides Val-Pro-Pro and Ile-Pro-Pro during ripening of different Swiss cheese varieties. J Dairy Sci. 2009;92:826-836.
104. Martin M, Wellner A, Ossowski I, etal. Identification and quantification of inhibitors for angiotensin-converting enzyme in hypoallergenic infant milk formulas. J Agric Food Chem. 2008;56:6333-6338.
105. Quiros A, del Mar CM, Ramos M, etal. Stability to gastrointestinal enzymes and structure-activity relationship of β-casein-peptides with antihypertensive properties. Peptides. 2009;30:1848-1853.
106. Wu J, Aluko RE, Nakai S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: quantitative structure-activity relationship study of di- and tripeptides. J Agric Food Chem. 2006;54:732-738.
107. Nakamura Y, Yamamoto N, Sakai K, etal. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci. 1995;78:777-783.
108. Tauzin J, Miclo L, Gaillard JL. Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein. FEBS Lett. 2002;531:369-374.
109. Hernandez-Ledesma B, Amigo L, Ramos M, etal. Application of high-performance liquid chromatography-tandem mass spectrometry to the identification of biologically active peptides produced by milk fermentation and simulated gastrointestinal digestion. J Chromatogr A. 2004;1049:107-114.
110. Minervini F, Algaron F, Rizzello CG, etal. Angiotensin I-converting-enzyme-inhibitory and antibacterial peptides from Lactobacillus helveticus PR4 proteinase-hydrolyzed caseins of milk from six species. Appl Environ Microbiol. 2003;69:5297-5305.
111. Mullally MM, Meisel H, FitzGerald RJ. Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine beta-lactoglobulin. FEBS Lett. 1997;402:99-101.
112. Pihlanto-Leppala A, Koskinen P, Piilola K, etal. Angiotensin I-converting enzyme inhibitory properties of whey protein digests: concentration and characterization of active peptides. J Dairy Res. 2000;67:53-64.
113. Hernandez-Ledesma B, Ramos M, Recio I, etal. Effect of beta-lactoglobulin hydrolysis with thermolysin under denaturing temperatures on the release of bioactive peptides. J Chromatogr A. 2006;1116:31-37.
114. Nakamura Y, Kajimoto O, Kaneko K, etal. Effects of the liquid yogurts containing "lactotripeptide (VPP, IPP)" on high-normal blood pressure. J Nutr Food. 2004;7:123-137.
115. Saito T, Nakamura T, Kitazawa H, etal. Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese. J Dairy Sci. 2000;83:1434-1440.
116. Hayes M, Stanton C, Slattery H, etal. Casein fermentate of Lactobacillus animalis DPC6134 contains a range of novel propeptide angiotensin-converting enzyme inhibitors. Appl Environ Microbiol. 2007;73:4658-4667.
117. Quirós A. Identification of novel antihypertensive peptides in milk fermented with Enterococcus faecalis. Int Dairy J. 2007;7:33-41.
118. Quiros A, Hernandez-Ledesma B, Ramos M, etal. Angiotensin-converting enzyme inhibitory activity of peptides derived from caprine kefir. J Dairy Sci. 2005;88:3480-3487.
119. Geerlings A, Villar IC, Hidalgo ZF, etal. Identification and characterization of novel angiotensin-converting enzyme inhibitors obtained from goat milk. J Dairy Sci. 2006;89:3326-3335.
120. Rodríguez-Figueroa JC, Reyes-Díaz R, González-Córdova AF, etal. Angiotensin-converting enzyme inhibitory activity of milk fermented by wild and industrial Lactococcus lactis strains. J Dairy Sci. 2010;93:5032-5038.
121. Chen Y, Wang Z, Chen X, etal. Identification of angiotensin I-converting enzyme inhibitory peptides from koumiss, a traditional fermented mare's milk. J Dairy Sci. 2010;93:884-892.
122. Tavares T, Contreras MD, Amorim M, etal. Novel whey-derived peptides with inhibitory effect against angiotensin-converting enzyme: in vitro effect and stability to gastrointestinal enzymes. Peptides. 2011;32:13-19.
123. Murakami M, Tonouchi H, Takahashi R, etal. Structural analysis of a new anti-hypertensive peptide (β-lactosin B) isolated from a commercial whey product. J Dairy Sci. 2004;87:1967-1974.
124. Hernandez-Ledesma B, Miguel M, Amigo L, etal. Effect of simulated gastrointestinal digestion on the antihypertensive properties of synthetic β-lactoglobulin peptide sequences. J Dairy Res. 2007;74:336-339.
125. Miguel M, Muguerza B, Sanchez E, etal. Long-term blood pressure-lowering effect of milk fermented by Enteroccoccus faecalis CECT 5728 in spontaneously hypertensive rats. Br J Nutr. 2005;93:1-9.
126. Nurminen ML, Sipola M, Kaarto H, etal. Alpha-lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci. 2000;66:1535-1543.
127. Sipola M, Finckenberg P, Korpela R, etal. Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res. 2002;69:103-111.
128. Sipola M, Finckenberg P, Santisteban J, etal. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol. 2001;52:745-754.
129. Chen GW, Tsai JS, Sun Pan B. Purification of angiotensin I-converting enzyme inhibitory peptides and antihypertensive effect of milk produced by protease-facilitated lactic fermentation. Int Dairy J. 2007;17:641-647.
130. Tsai JS, Chen TJ, Pan BS, etal. Antihypertensive effect of bioactive peptides produced by protease-facilitated lactic acid fermentation of milk. Food Chem. 2008;106:552-558.
131. Sanchez D, Kassan M, Contreras MD, etal. Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits. Pharmacol Res. 2011;63:398-404.
132. Hata Y, Yamamoto M, Ohni M, etal. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr. 1996;64:767-771.
133. Kajimoto O, Nakamura Y, Yada H, etal. Hypotensive effects of sour milk in subjects with mild or moderate hypertension. Nihon Eiyo Shokuryo Gakkai Shi. 2001;54:347-354.
134. Itakura H, Ikemoto S, Tereda S, etal. The effect of sour milk on blood pressure in untreated hypertensive and normotensive subjects. Nihon Rinshō Eiyō Gakkai Zasshi. 2001;23:26-31.
135. Kajimoto O, Kurosaki T, Mizutani J, etal. Antihypertensive effects of liquid yogurts containing "lactotripeptides (VPP, IPP)" in mild hypertensive subjects. J Nutr Food. 2002;5:55-66.
136. Seppo L, Kerojoki O, Soumalainen T, etal. The effect of a Lactobacillus helveticus LBK-16H fermented milk on hypertension: a pilot study on humans. Milchwissenschaft. 2002;57:124-127.
137. Seppo L, Jauhiainen T, Poussa T, etal. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr. 2003;77:326-330.
138. Pins JJ, Keenan JM. The antihypertensive effects of a hydrolyzed whey protein isolate supplement (BioZate 1): a pilot study [abstract]. FASEB J. 2003;17:A1110.
139. Mizushima S, Ohshige K, Watanabe J, etal. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens. 2004;17:701-706.
140. Townsend RR, McFadden CB, Ford V, etal. A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Am J Hypertens. 2004;17:1056-1058.
141. Tuomilehto J, Lindstrom J, Hyyrynen J, etal. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Hum Hypertens. 2004;18:795-802.
142. Mizuno S, Matsuura K, Gotou T, etal. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr. 2005;94:84-91.
143. Jauhiainen T, Collin M, Narva M, etal. Effect of long-term intake of milk peptides and minerals on blood pressure and arterial function in spontaneously hypertensive rats. Milchwissenschaft. 2005;60:358-363.
144. Engberink MF, Schouten EG, Kok FJ, etal. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hipertensión. 2008;51:399-405.
145. van der Zander K, Bots ML, Bak AA, etal. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Am J Clin Nutr. 2008;88:1697-1702.
146. van der Zander K, Jakel M, Bianco V, etal. Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects. J Hum Hypertens. 2008;22:804-806.
147. van Mierlo LA, Koning MM, van der Zander K, etal. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies. Am J Clin Nutr. 2009;89:617-623.
148. de Leeuw PW, van der Zander K, Kroon AA, etal. Dose-dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects. Blood Press. 2009;18:44-50.
149. Nakamura T, Mizutani J, Sasaki K, etal. Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: a preliminary study. J Med Food. 2009;12:1221-1226.
150. Yamasue K, Morikawa N, Mizushima S, etal. The blood pressure lowering effect of lactotoripeptides and salt intake in 24-h ambulatory blood pressure measurements. Clin Exp Hypertens. 2010;32:214-220.
151. Boelsma E, Kloek J. IPP-rich milk protein hydrolysate lowers blood pressure in subjects with stage 1 hypertension, a randomized controlled trial. Nutr J. 2010;9:52.
152. Boelsma E, Kloek J. Lactotripeptides and antihypertensive effects: a critical review. Br J Nutr. 2009;101:776-786.
153. Pripp AH. Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52:1-9.
154. Xu JY, Qin LQ, Wang PY, etal. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition. 2008;24:933-940.
155. Usinger L, Ibsen H, Jensen LT. Does fermented milk possess antihypertensive effect in humans? J Hypertens. 2009;27:1115-1120.
156. Ballard KD, Bruno RS, Seip RL, etal. Acute ingestion of a novel whey-derived peptide improves vascular endothelial responses in healthy individuals: a randomized, placebo controlled trial. Nutr J. 2009;8:34.
157. Hirota T, Nonaka A, Matsushita A, etal. Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels. 2011;26:549-556.
158. Mullally MM, Meisel H, FitzGerald RJ. Synthetic peptides corresponding to alpha-lactalbumin and beta-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. Biol Chem Hoppe Seyler. 1996;377:259-260.
159. Petersen BL, Ward LS, Bastian ED, etal. A whey protein supplement decreases post-prandial glycemia. Nutr J. 2009;8:47.
160. Nilsson M, Holst JJ, Bjorck IM. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr. 2007;85:996-1004.
161. Drucker DJ. Enhancing the action of incretin hormones: a new whey forward? Endocrinology. 2006;147:3171-3172.
162. European Food Safety Authority. Scientific opinion of the Panel on Dietetic Products, Nutrition and Allergies on a request from Valio Ltd. on the scientific substantiation of a health claim related to Lactobacillus helveticus fermented Evolus® low-fat milk products and reduction of arterial stiffness. EFSA J 2008;824:1-2.